Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030

Tracking the healthcare innovation
Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market

Free (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral,
Insights Plasmid DNA and Other Vectors)
2019 © Roots Analysis
CONFIDENTIAL | 11
www.rootsanalysis.com
Note on Confidentiality
Our clients are extremely competitive. The confidentiality of companies’ plans and data is obviously critical. Roots Analysis will protect the
confidentiality of all such client information.
Similarly, business research and management consulting is a competitive business. We view our approaches and insights as proprietary
and, therefore, look to our clients and prospective clients to protect Roots Analysis’ interests in our presentations, methodologies and
analytical techniques. Under no circumstances should this material be shared with any third party without our prior written consent.
Copyright © 2019 Roots Analysis Private Ltd.
22
Contents
▪ Context
1
▪ Project Objectives
2
▪ Project Approach
3
▪ Example Highlights
4
▪ Chapter Outlines
5
▪ Table of Contents
6
33
Context
The growing pipeline of cell and gene therapies has led to an increase in demand for high quality gene delivery vehicles and,
therefore, has created significant opportunities for companies with expertise in manufacturing viral and non viral vectors
USD After the approval of multiple

Growing Pipeline
500+ 2,500+ Billion 30+ genetically-modified therapies, the
of Genetically- Candidates being Clinical trials have Invested in need for robust gene delivery tools
evaluated across been registered / companies to
Modified is anticipated to increase as more
various stages of initiated since 1989, support therapy
Therapies development across the globe development companies are investing in cell and
gene therapies
High Capital Process Limited Existing concerns in this field have

Investment Complexity Expertise led many players to outsource
Vector
vector and gene therapy
Manufacturing In the establishment The use of living cells Of therapy developers
and maintenance of adds to the difficulties involved in the market manufacturing operations, while
Challenges
facilities dedicated associated with makes the processes others continue to rely on technical
to vector production manufacturing relatively less reliable innovation
Increasing expenditure by public

Current Industry
180+ Players 140+ Agreements ~20% CAGR
and private healthcare groups and
Presently claim to Indicative of the Anticipated annualized advances in complex production
Landscape and
have the capabilities growing demand for growth of the vector protocols, are anticipated to
Upcoming Trends to develop vectors manufacturing and gene therapy sustain growth within this lucrative
and gene therapies services in the domain manufacturing market market
44
Project Objectives (1/2)
Roots Analysis has done a detailed report on Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing
covering various important aspects of the industry and identifying key future growth opportunities
Market Demand Capacity Key

Landscape Analysis Analysis Insights
A detailed assessment of the current market An informed estimate of the annual demand for A detailed capacity analysis, taking into An in-depth analysis of viral vector and plasmid
landscape, featuring a list of 180+ Industry and viral and non-viral vectors based on various consideration the individual development and DNA manufacturers, featuring three schematic
Non-Industry players manufacturing viral vectors, relevant parameters, such as target patient manufacturing capacities of various (small-sized, representations.1
non-viral vectors and gene therapies, and population, dosing frequency and dose strength. mid-sized, large and very large) viral vectors and
analysis based on a number of parameters.1 plasmid DNA manufacturers, using data collated
from both secondary and primary sources.
Recent Cost Price Emerging Company

Collaborations Analysis Vectors Profiles
An analysis on the recent trends within the vector An analysis of the various factors that are likely An overview of other viral / non-viral gene Elaborate profiles of key players based in North
and gene therapy manufacturing market, to influence the pricing of vectors, featuring delivery approaches that are currently being America, Europe and Asia-Pacific. Each profile
highlighting various partnerships that were different models / approaches that may be researched for the development of therapies featuring brief overview of the company /
reported by stakeholder companies in the period adopted by product developers / manufacturers involving genetic modification. organization, its financial performance (if
between 2015 and 2018. in order to decide the prices of proprietary available), information on its manufacturing
vectors. facilities, vector manufacturing technology and
an informed future outlook.
Note 1: The market landscape presents distribution of players across year of establishment, scale of production, type of vectors manufactured, location of manufacturing facilities, applications of vectors (in gene therapy, cell therapy, vaccines and
others), and purpose of production (fulfilling in-house requirements / for contract services).
Note 2: The three schematic representations feature [A] a three dimensional grid analysis, representing the distribution of vector manufacturers (on the basis of type of vector) across various scales of operation and purpose of production (in-house
operations and contract manufacturing services), [B] a logo landscape of viral vector and plasmid DNA manufacturers based on the type (industry and non-industry) and the size of the industry player (small-sized, mid-sized and large companies), and
[C] a schematic world map representation, highlighting the geographical locations of vector manufacturing hubs. 2019 © Roots Analysis
55
Project Objectives (2/2)
Roots Analysis has done a detailed report on Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing
covering various important aspects of the industry and identifying key future growth opportunities
Companies Interviewed
Drivers and Market Forecast Primary

Challenges Growth Potential Research
A discussion on the factors driving the market and An informed estimate of the likely evolution of the Detailed transcripts of over 10 interviews held
the various challenges associated with the vector market over the period 2019-2030, including the with representatives of renowned industry and
production process. likely distribution of the current and future non-industry players that are engaged in the
opportunity across a variety of market segments 1 manufacturing of viral vectors, non-viral
vectors and gene therapies2
Note 1: The projected opportunity has been analyzed across the following segments [A] type of vectors (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), [B] applications (gene therapy, cell therapy and vaccines), [C] therapeutic area (oncological disorders, inflammation &
immunological diseases, neurological disorders, ophthalmic disorders, muscle disorders, metabolic disorders, cardiovascular disorders and others), [D] scale of operation (preclinical, clinical and commercial) and [E] geography (North America, Europe, Asia Pacific and rest of the world).
Note 2: The interviews were held with Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences), Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals), Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences), Olivier Boisteau, (Co-Founder /
President, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells), Laurent Ciavatti (Business Development Manager, Clean Cells), Joost van den Berg (Director, Amsterdam BioTherapeutics Unit), Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General
Hospital), Colin Lee Novick (Managing Director, CJ Partners), Cedric Szpirer (Executive & Scientific Director, Delphi Genetics), Semyon Rubinchik (Scientific Director, ACGT), Alain Lamproye (President of Biopharma Business Unit, Novasep), Astrid Brammer (Senior Manager Business
Development, Richter-Helm), Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing), Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Marketing Manager, Plasmid Factory), and Nicolas Grandchamp (R&D Leader, GEG Tech). 2019 © Roots Analysis
66
Project Approach
Secondary Research Primary Research
Investor
Information Presentations
Annual Reports Press Releases Interviews conducted with
Sources CEOs and Directors of industry and
Industry Other Analysts’ non-industry stakeholders
SEC Filings
Databases Opinions
Industry Key Growth Future Trends /

Market Insights Landscape Drivers
Challenges
Scenarios
Specific Model Patient Population Competitive Current Price Points Global Increasing
Parameters (Clinical / Commercial) Landscape and Likely Decline Demand
Type of Application Therapeutic Scale of

Regions
Vector Area Area Operation
Market Forecast
Outputs Overall Market Forecast till 2030 is segmented by Diseases, Neurological Disorders, Ophthalmic Disorders, Muscle Disorders,
▪ Type of Vector(s): AAV vector, Adenoviral vector, Lentiviral vector, Retroviral Metabolic Disorders, Cardiovascular Disorders and Others
vector, Plasmid DNA and Other Vectors ▪ Scale of Operation: Preclinical, Clinical and Commercial
▪ Application Area(s): Gene Therapy, Cell Therapy and Vaccines ▪ Region(s): North America, Europe and Asia Pacific
▪ Therapeutic Area(s): Oncological Disorders, Inflammation & Immunological
Industry Stakeholders Client Feedback

Data Triangulation In-house Experts
(via Primary Research) (ongoing pre / post project release)
77
Example highlights
Eminent representatives agree to the need for outsourcing vector and gene therapy manufacturing, highlighting
the challenges and drivers of the contract services market in this domain
High Cost of Challenges Stringent Regulatory Final Product Need for Changes in
Manufacturing Viral Associated with Requirements for Contamination- Operational Models to
Vectors Production Output Human Clinical Trials related Concerns Sustain Market Growth
Executive & Scientific Director, Director, Scientific Director, Marketing Manager, R&D Leader,
a small Belgian company a US-based hospital a small US-based company a small German company a small French company
Growing Preference Capacity Expansions Increasing Involvement Advanced Technical Novel Vectors based on
to Outsource Vector to Accommodate for of Spin-offs / Start-ups Solutions to Transposons and Sendai
Manufacturing Commercial Scale from the Academic Manufacturing Virus to Address Existing
Operations Operations Sector Concerns Challenges
Scientific Director, President of Biopharma Business, President / Co-Founder, Chief Commercial Officer, Managing Director,
a small US-based company a large French company a France-based mid-sized company a mid-sized US-based company a small Japanese company
Vectors and Gene Therapy Manufacturing Market

Rising Opportunities Anticancer Therapies Roots Analysis Survey, Distribution by Respondents
from Late-stage Presently Contribute
Genetically Modified the Most to the 27% 23% CXO Level
Contract
Therapies Demand for Vectors 46% Industry
39%
Services Senior
Business Development Manager, Executive & Scientific Director, 54% Management
Academia 61% In-house
a France-based mid-sized a Belgium-based small-sized Middle
company company Management
50%
88
Example highlights
Close to 100 industry players and over 80 non-industry players, based in different regions across the globe, claim
to manufacture different types of viral and non-viral vectors in-house or on contract basis
List of Vectors and Gene Therapy Manufacturers
Industry Players
Company Year of Type of Vector Purpose of Production
S. No. Headquarters Production Capacity
Name Establishment AAV Adenoviral Lentiviral Retroviral Plasmid DNA Others Contract Manufacturing In-House
16 2009 ✓ ✓ ✓ ✓ ✓ ✓ ✓ 20mL to 200L
23 2001 ✓ ✓ ✓
Distribution of Vectors and Gene Therapy Manufacturers by Type of Vectors1
39 1998 ✓ ✓ ✓
48 1995 ✓ ✓ ✓ 58% 41% 56%

Distribution of Developers by Size and Geography
62 2005 ✓ ✓ ✓
70 2012 ✓ ✓ ✓
Information on over 95+ Industry Players is available in the full report
Non-Industry Players
Academia Year of Type of Vector AAV Vectors Purpose
Adenoviral of Production
Vectors Lentiviral Vectors
S. No. Headquarters Production Capacity
Name Establishment AAV Adenoviral Lentiviral Retroviral Plasmid DNA Others In-House Contract Manufacturing
29% 27% 24%
5 2012 ✓ ✓ ✓ ✓ ✓ 2L to 400L
35 1885 ✓ ✓ ✓ ✓ ✓ ✓ ✓ 20ml to 200L
58 2014 ✓ ✓ ✓
66 2009 ✓
≤ 50 Employees 51-500 Employees 500+ Employees
Retroviral Vectors Plasmid DNA Other Vectors
76 1962 ✓ ✓ ✓
Information on 85+ Non-Industry Players is available in the full report
Note 1: Players offering more than one type of vector have been counted multiple times in this representation 2019 © Roots Analysis
99
Example highlights
The market is fragmented, featuring both established players and small firms that claim to be capable of
manufacturing different vectors, at varying scales of operation and for a range of applications
Vectors and Gene Therapy Vectors and Gene Therapy Vectors and Gene Therapy
Manufacturers Manufacturers Manufacturers
Distribution by Company Size Scale of Operation and Type of Vector Distribution by Type of Application and Region1
Legend Small Mid-sized Large Legend CMO In-house Both
Distribution by Geography
Retroviral
Gene Therapy
35+ Cell Therapy
2%
7%
Small-sized Industry Players Vaccines
Adenoviral
Others
RoW
44%
Asia-Pacific
Lentiviral
Europe
20+ 43%
North America
Mid-sized Industry Players
47%
AAV
22%
Plasmid DNA
20+ 23%
1
Large Industry Players

12%
Lab Clinical Commercial
1
Note 1: Companies offering vectors for more than one type of application have been counted multiple times in this representation 2019 © Roots Analysis
10
10
Example highlights
In order to acquire competencies across the supply chain and cater to the evolving needs of clients / sponsors,
companies have established presence across different regions; the US and EU are considered as key hubs
Full list of 200+ manufacturing facilities for vector and
Vectors and Gene Therapy Manufacturers gene therapy manufacturing is available in the report
titled “Viral Vectors, Non-Viral Vectors and Gene
Distribution by Location of Manufacturing Facility Therapy Manufacturing Market (3rd Edition), 2019-
Scale of Operation Preclinical Clinical Commercial 2030 (Focus on AAV, Adenoviral, Lentiviral,
Retroviral, Plasmid DNA and Other Vectors)”
Florida Germany Finland

AGTC Richter-Helm BioLogics FinVector
Brammer Bio Company C National Virus Vector Laboratory, Japan
Company A Company D University of Eastern Finland Core Facility for Therapeutic Vectors,
PlasmidFactory Company I Institute of Medical Science Research
Texas BioNTech Innovative Manufacturing Hospital
VGXI Service Kobe Biomedical Accelerator
Center for Cell & Gene Therapy Company M
Baylor College of Medicine Company N
Belgium
Iowa Company J
Viral Vector Core, University United Kingdom Company K
of Iowa Cobra Biologics Novasep
Carver College of Medicine Wolfson Gene Therapy Unit (WGTU), Leuven Viral Vector Core China
University College of London The HongKong Institute of
Massachusetts Company E Biotechnology
Batavia Biosciences Company F Applied Biological Materials
Gene Transfer Vector Core Viral Vector Core, The Jenner Company O
Viral Gene Transfer Core, MIT Institute Italy Company P
Viral Vector Core, University of Vector Core,
Massachusetts Medical School Telethon Institute of Genetics and
Company B Medicine
Company L
Michigan France Australia
Vector Core, University of Vector Core of Gene Therapy University of Adelaide
Michigan Medical Center Laboratory of Nantes
Company G
Ohio Genethon Switzerland
Abeona Therapeutics Sanofi Company M
Cincinnati Children's Hospital Medical Company H Celonic New Zealand
Center Company Q
Note: Complete list of the companies with their vector manufacturing facilities is available in full report 2019 © Roots Analysis
11
11
Example highlights
The increasing interest in this field is reflected in the recent partnership activity, involving manufacturing services
for diverse range of vectors, featuring the participation of both international and indigenous stakeholders
Partnerships and Collaborations Partnerships and Collaborations Partnerships and Collaborations
Distribution by Type of Partnership1 Distribution by Type of Vector2 Geographical Activity
Relative Distribution
Intercontinental Partnerships & Collaborations
2019 19% AAV 43%
xx
19% Lentiviral 23% 16% xx

2018
North America Europe Asia-Pacific

21% Plasmid DNA xx%
2017
xx xx
Adenoviral xx%
2016 25%
xx
Retroviral xx%
2015 16%
Intercontinental Partnerships & Collaborations
Others 5%
Product Development Manufacturing North America Europe Asia-Pacific
Product / Technology Licensing Acquisition / Merger 32% 28% xx
Viral Vector (Type
xx%
Services Alliance Others Unknown)
Process Development / Optimization
Between 2015 and 2018, partnership activity in this domain Stakeholders have inked relatively more deals for process / Examples of firms that have signed multiple deals within
has increased at a CAGR of over 15%. In fact, nearly 50% product development, manufacturing and licensing of AAV North America include bluebird bio and Vigene
of the deals were established post 2017, with maximum vectors since 2018, while lentiviral vectors were the second Biosciences; active players based in other regions include
activity being reported for manufacturing purposes most popular type of vector, in terms of the deals inked CEVEC Pharmaceuticals, Lonza, and Oxford Biomedica
Note 1: For 2019, the partnerships have been captured till August 2019
Note 2: Partnerships with more than one type of vector have been counted multiple times in this representation 2019 © Roots Analysis
12
12
Example highlights
The installed global vector manufacturing capacity is currently estimated to be over 60 thousand liters, spread
across various global regions Comprehensive capacity analysis, providing a holistic view on the
supply-side of the market, is available in the report titled “Viral
Vectors and Gene Therapy Manufacturing Market: Capacity Analysis Vectors, Non-Viral Vectors and Gene Therapy Manufacturing
Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral,
Distribution of Installed, Global Manufacturing Capacity for Viral Vectors and Plasmid DNA Lentiviral, Retroviral, Plasmid DNA and Other Vectors)””
North America X Liters Europe X Liters Asia-Pacific X Liters
Example Players
Example Players
Example Players
Vector Manufacturing Capacity Analysis:

Range of Installed Capacity by Company Size
Total Installed Capacity (in Liters)
Mean Capacity:
XX L
Executive Insights
President of Biopharma Business Unit, a large CMO
Mean Capacity:
XX L “ Currently, most of our customers demand services at the clinical scale for viral
vectors. The commercial capacity for these vectors is therefore, limited.
Presently, we are trying to expand our cGMP capabilities to offer services at the
”
Mean Capacity: commercial scale.
XX L
Small-Sized Mid-Sized Large and Very

Companies Companies Large Companies
13
13
Example highlights
The demand for vectors is high, raising sponsor companies’ expectations from manufacturing service providers
for solutions to deal with the growing need to address the existing capacity shortage
Viral and Non-Viral Vectors1 Viral and Non-Viral Vectors

Current (2019) and Future Demand (2030), By Geography Demand Vs Supply Analysis (in Litres)
Legend North America Europe Asia-Pacific Rest of the World Legend Demand Supply
Supply Side2
Volume (in L)
~Y Thousand Total Capacity (in L) = ∑Capacityi, where i is capacity of manufacturers of vectors
~xx Mn Patients Demand Side3
Scenario III: +Z%
xx% Total Demand (in L) = ∑Demandi, where i is demand from clinical and commercial
Growth vector based therapies
~xx Mn Rate X% Scenario II: +Y%
Growth
X% xx%
Rate
~xx Mn
Scenario I: +X%
Growth
Rate X%
Under Supply
~xx Mn
xx%
Growth
Rate X% Executive Insight Over Demand
Head of Gene Therapy – Mid-sized company
Current Supply
“
~ X Thousand Driven by a number of late-stage
xx% Patients gene therapy products, the The available vector manufacturing capacity is insufficient for handling the estimated current
xx% demand for vector manufacturing xx% demand. The situation is unlikely to improve as more cell and gene therapies enter the market.
xx% services is expected to increase Left unchecked, the demand may soon overwhelm the existing capacity to supply vectors.
”
significantly in the foreseen However, stakeholders are expanding existing capabilities and upgrading legacy technologies
future. to accommodate larger scale contracts, without significantly compromising on quality
xx%
2019 2030 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Note 1: In terms of number of patients being treated with vector-based therapies (taking into consideration marketed and clinical stage therapies)
Note 2: Supply side representation takes into consideration the current installed capacity of players providing contract manufacturing services for vectors
Note 3: Demand side is depicted based on the commercial demand for the therapies that require vectors 2019 © Roots Analysis
14
14
Example highlights
Novel viral and bacterial strains, such as the Sendai virus and Bifidobacterium longum, are currently being
investigated as vectors to develop genetically modified therapies / vaccines Detailed information on the other upcoming vectors is
available in the report titled “Viral Vectors, Non-Viral
Vectors and Gene Therapy Manufacturing Market (3rd
Upcoming Vectors Edition), 2019-2030 (Focus on AAV, Adenoviral,
Developer / CMO Landscape and Executive Insights Lentiviral, Retroviral, Plasmid DNA and Other Vectors)”
Virus Based Bacteria Based Others (DNA / Transposon)
“
We believe that a few novel vectors, having low immunogenicities and
Upcoming Vector Types
targeting different cell types, are likely to soon be introduced into the
market. I am also aware of companies that are researching different (better)
”
versions of adeno-associated viral vectors.
▪ Alphavirus
- Executive & Scientific Officer,
▪ Anc80 (Synthetic AAV)
A small-sized company
▪ Cytomegalovirus
▪ Herpes Simplex Virus ▪ Minicircle DNA
▪ Bifidobacterium Longum ▪
“
▪ Modified Vaccinia Ankara Sleeping Beauty
▪ Listeria Monocytogenes ▪ PiggyBac
▪ Myxoma Virus We have worked with a couple of transposons and the Vaccinia viruses as
▪ Sendai Virus
vectors, the latter cannot exactly be regarded as a novel approach. I believe,
▪ Sindbis Virus
▪ Varicella Zoster Virus transposons and Sendai virus are the only novel vector systems that are
”
likely to soon become popular.
- Managing Director,
Landscape
A management consulting firm for regenerative medicines
“ To overcome the challenges associated with the production of contaminant

free final product using conventional plasmids, we are developing a
minicircle DNA vector, which are devoid of antibiotic resistance genes and
prokaryotic plasmid components, which are crucial for the replication of
Global Hubs
constructs in bacteria.
Note: The companies (developer / CMO) shown here may not be exhaustive
- Project Manager and Marketing Manager,
- a small-sized company
”
15
15
Example highlights
In the long-term, the forecasted future opportunity is anticipated to be higher for gene and cell therapies targeting
oncology; the revenue share is likely to be well distributed across both in-house and contract service providers
Manufacturing Market Manufacturing Market Manufacturing Market
Distribution by Type of Therapy2 Distribution by Therapeutic Area3 Distribution by In-House vs Contract
USD Billion USD Billion USD Billion
Gene Therapy USD X MN USD X MN
USD X MN Contract Manufacturing
USD X MN USD X MN USD X MN
Therapy Type 2 USD X MN USD X MN In-Hosue Manufacturing
Therapy Type 3
XX
Additional potential till 2030

XX
Likely market size in 2025

XX
XX
XX
XX
XX
XX
XX
XX
Therapeutic Area 8
2025 2030 Oncology Therapeutic Area 2 2025 2030
Therapeutic Area 7
Therapeutic Area 3 Therapeutic Area 6
Therapeutic Area 4 Therapeutic Area 5
Note 1: Illustrations are not as per actual scale
Note 2: The Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 takes into consideration three types of therapies, namely gene therapies, T-Cell therapies and vaccines
Note 3: The Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 takes into consideration eight types of therapeutic areas, namely oncology, inflammation and immunology, neurological
Disorders, ophthalmic disorders, muscular disorders, metabolic disorders, cardiovascular disorders and others 2019 © Roots Analysis
16
16
Example highlights
As new therapies are approved, a significant proportion of the market share is likely to be driven by commercial-
scale operations, specifically for viral vectors; North America is expected to lead the market evolution
Manufacturing Market Manufacturing Market Manufacturing Market
Distribution by Scale of Operation2 Distribution by Type of Vectors3 Distribution by Geography4
USD Billion USD Billion
North America
CAGR
Commercial
Region 2
Scale of Operation 2 Region 3
Scale of Operation 3 Region 4 XX
XX
XX
XX
Vector Type 1
XX XX
XX Vector Type 2 XX XX
XX Vector Type 6 Vector Type 3 XX
XX Vector Type 5
XX
Vector Type 4
XX
Note: The size of the bubble represents the likely market
share in the long-term (2030)
2025 2030 Market Share 2025 2030

(Mid Term)
Note 1: Illustrations are not as per actual scale

Note 2: The Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 takes into consideration three types of scales of operations, namely preclinical, clinical and commercial
Note 3: The Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 takes into consideration six types of vectors, namely AAV, adenoviral, lentiviral, retroviral, plasmid DNA and others
Note 4: The Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 takes into consideration four geographies, namely North America, Europe, Asia-Pacific and rest of the world 2019 © Roots Analysis
17
17
Get in touch to know more!
sales@rootsanalysis.com
Report Details
▪Product Code: RA100152
▪Pages: 423
▪Publication Date: 03 October 2019
▪Number of Tables: 189
▪Number of Figures: 149
Pricing Details
▪Single-User License: USD 4,499
▪Site License: USD 7,999
▪Enterprise License: USD 15,999
18
18
Purchase Your Copy Today!
Scan and email this form to sales@rootsanalysis.com
LICENSE TYPE (tick one)

Report Title: RA100152: Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030
USD ($) EUR (€) GBP (£)
Single User License $4,499 €3,999 £3,499
Site License $7,999 €7,049 £6,199
Enterprise License $15,999 €14,099 £12,399
CUSTOMER DETAILS
Name: Email:
Job Title: Company:
Address:
City: Country:
ZIP Code: Phone:
PAYMENT DETAILS
Select preferred currency option
USD ($)
EUR (€)
GBP (£)
Please invoice my company for _______________
PAYMENT AUTHORIZATION NOTE

The prices mentioned on this form and on the website are inclusive of all
Sign below to authorize the payment taxes. You can also buy the reports online by visiting the page
www.rootsanalysis.com/reports. For any queries, write to us at
sales@rootsanalysis.com. Please note that by ordering from Roots
Analysis Private Limited, you are agreeing to the Terms and Conditions at
_____________________________________________________ Date ________________ www.rootsanalysis.com/terms 2019 © Roots Analysis
19
19
Chapter Outlines (1/2)
▪ Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the vector and gene therapy manufacturing market in the short
to mid-term, and long term.
▪ Chapter 3 is a general introduction to the various types of viral and non-viral vectors. It includes a detailed discussion on the design, manufacturing requirements, advantages, limitations and applications
of currently available gene delivery vehicles. The chapter also provides a brief description of the clinical and approved pipeline of genetically modified therapies. Further, it includes a review of the latest
trends and innovations in the contemporary vector manufacturing market.
▪ Chapter 4 provides a detailed overview of around 80 companies, featuring both contract service providers and in-house manufacturers that are actively involved in the production of viral vectors and / or
gene therapies utilizing viral vectors. The chapter provides details on the year of establishment, scale of production, type of viral vectors manufactured (AAV, adenoviral, lentiviral, retroviral and others),
location of manufacturing facilities, applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of production (fulfilling in-house requirements / for contract services).
▪ Chapter 5 provides an overview of around 30 industry players that are actively involved in the production of plasmid DNA and other non-viral vectors and / or gene therapies utilizing non-viral vectors.
The chapter provides details on the year of establishment, scale of production, location of manufacturing facilities, applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose
of vector production (fulfilling in-house requirements / for contract services).
▪ Chapter 6 provides an overview of around 80 non-industry players (academia and research institutes) that are actively involved in the production of vectors (both viral and non-viral) and / or gene
therapies. The chapter provides details on the year of establishment, scale of production, location of manufacturing facilities, type of vectors manufactured (AAV, adenoviral, lentiviral, retroviral, plasmid
DNA and others), applications of vectors (gene therapies, cell therapies, vaccines and others) and purpose of vector production (fulfilling in-house requirements / for contract services).
▪ Chapter 7 features detailed profiles of the US based contract service providers / in-house manufacturers that possess commercial scale capacities for the production of viral vectors / plasmid DNA. Each
profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience and an informed future outlook.
▪ Chapter 8 features detailed profiles of EU based contract service providers / in-house manufacturers that possess commercial scale capacities for the production of viral vectors / plasmid DNA. Each
profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience, and an informed future outlook.
▪ Chapter 9 features detailed profiles of Asia-Pacific based contract service provider(s) / in-house manufacturer(s) that possess commercial scale capacities for production of viral vectors / plasmid DNA.
Each profile presents a brief overview of the company, its financial information (if available), details on vector manufacturing facilities, manufacturing experience, and an informed future outlook.
▪ Chapter 10 provides detailed information on other viral / non-viral vectors (including alphavirus vectors, Bifidobacterium longum vectors, Listeria monocytogenes vectors, myxoma virus based vectors,
Sendai virus based vectors, self-complementary vectors (improved versions of AAV), and minicircle DNA and Sleeping Beauty transposon vectors (non-viral gene delivery approach)) that are currently
being utilized by pharmaceutical players to develop gene therapies, T-cell therapies and certain vaccines, as well. This chapter presents overview on all the aforementioned types of vectors, along with
examples of companies that use them in their proprietary products. It also includes examples of companies that are utilizing specific technology platforms for the development / manufacturing of some of
these novel vectors.
▪ Chapter 11 features an elaborate analysis and discussion of the various collaborations and partnerships related to the manufacturing of vectors or gene therapies, which have been inked amongst
players. It includes a brief description of the purpose of the partnership models (including licensing agreements, mergers / acquisitions, product development, service alliances, manufacturing, and others)
that have been adopted by the stakeholders in this domain, since 2015. It consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore,
we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.
▪ Chapter 12 presents a collection of key insights derived from the study. It includes a grid analysis, highlighting the distribution of viral vectors and plasmid DNA manufacturers on the basis of their scale
of production and purpose of manufacturing (fulfilling in-house requirement / contract service provider). In addition, it consists of a logo landscape, representing the distribution of viral vector and plasmid
DNA manufacturers based on the type of organization (industry / non-industry) and size of employee base. The chapter also consists of six world map representations of manufacturers of viral / non-viral
vectors (lentiviral, adenoviral, AAV and retroviral vectors, and plasmid DNA), depicting the most active geographies in terms of the presence of the organizations. Furthermore, we have provided a
schematic world map representation to highlight the locations of global vector manufacturing hubs across different continents. 2019 © Roots Analysis
20
20
Chapter Outlines (2/2)
▪ Chapter 13 highlights our views on the various factors that may be taken into consideration while pricing viral vectors / plasmid DNA. It features discussions on different pricing models / approaches that
manufacturers may choose to adopt to decide the prices of their proprietary products.
▪ Chapter 14 features an informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based
therapies. This section offers an opinion on the required scale of supply (in terms of vector manufacturing services) in this market. For the purpose of estimating the current clinical demand, we
considered the active clinical studies of different types of vector-based therapies that have been registered till date. The data was analysed on the basis of various parameters, such as number of annual
clinical doses, trial location, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the marketed vector-based therapies,
based on various parameters, such as target patient population, dosing frequency and dose strength.
▪ Chapter 15 features an informed analysis of the overall installed capacity of the vectors and gene therapy manufacturers. The analysis is based on meticulously collected data (via both secondary and
primary research) on reported capacities of various small-sized, mid-sized and large companies, distributed across their respective facilities. The results of this analysis were used to establish an
informed opinion on the vector production capabilities of the organizations across different types of vectors (viral vectors, plasmid DNA, and both), scale of operation (clinical and commercial) and
geographies (North America, EU, Asia-Pacific and the rest of the world).
▪ Chapter 16 presents a comprehensive market forecast analysis, highlighting the likely growth of vector and gene therapy manufacturing market till the year 2030. We have segmented the financial
opportunity on the basis of [A] type of vectors (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), [B] applications (gene therapy, cell therapy and vaccines), [C]
therapeutic area (oncological disorders, inflammation & immunological diseases, neurological disorders, ophthalmic disorders, muscle disorders, metabolic disorders, cardiovascular disorders and
others), [D] scale of operation (preclinical, clinical and commercial) and [E] geography (North America, Europe, Asia Pacific and rest of the world). Due to the uncertain nature of the market, we have
presented three different growth tracks outlined as the conservative, base and optimistic scenarios.
▪ Chapter 17 provides details on the various factors associated with popular viral vectors and plasmid DNA that act as market drivers and the various challenges associated with the production process.
This information has been validated by soliciting the opinions of several industry stakeholders active in this domain.
▪ Chapter 18 presents insights from the survey conducted on over 160 stakeholders involved in the development of different types of gene therapy vectors. The participants, who were primarily Director /
CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.
▪ Chapter 19 summarizes the entire report. The chapter presents a list of key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to
determine the future of this segment of the industry.
▪ Chapter 20 is a collection of transcripts of the interviews conducted with representatives from renowned organizations that are engaged in the vector and gene therapy manufacturing domain. In this
study, we spoke to Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences), Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals), Jeffrey Hung
(Chief Commercial Officer, Vigene Biosciences), Olivier Boisteau, (Co-Founder / President, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells), Laurent Ciavatti (Business
Development Manager, Clean Cells), Joost van den Berg (Director, Amsterdam BioTherapeutics Unit), Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General
Hospital), Colin Lee Novick (Managing Director, CJ Partners), Cedric Szpirer (Executive & Scientific Director, Delphi Genetics), Semyon Rubinchik (Scientific Director, ACGT), Alain Lamproye (President
of Biopharma Business Unit, Novasep), Astrid Brammer (Senior Manager Business Development, Richter-Helm), Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing), Marco
Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Marketing Manager, Plasmid Factory), and Nicolas Grandchamp (R&D Leader, GEG Tech).
▪ Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures in the report.
▪ Chapter 22 is an appendix that provides the list of companies and organizations that have been mentioned in the report.
21
21
Table of Contents (1/5)
1 PREFACE 3.8.1. Types of Vector Manufacturers 5.2.3. Analysis by Geographical Location of Headquarters
1.1. Scope of the Report 3.8.2. Viral Vector Manufacturing Processes 5.2.4. Analysis by Geographical Location of Manufacturing Facilities
1.2. Research Methodology 3.8.2.1 Vector Production 5.2.5. Analysis by Type of Manufacturer
1.3. Chapter Outlines 3.8.2.2. Adherent and Suspension Cultures 5.2.6. Analysis by Purpose of Production
3.8.2.3. Unit Process Versus Multiple Parallel Processes 5.2.7. Analysis by Scale of Production
2 EXECUTIVE SUMMARY 3.8.2.4. Cell Culture Systems for Production of Viral Vectors 5.2.8. Analysis by Application Area
3.8.2.4.1. Small / Laboratory Scale Cell Culture Systems
3 INTRODUCTION 3.8.2.4.2. Large Scale Cell Culture Systems 6 VECTOR AND GENE THERAPY MANUFACTURERS (NON-INDUSTRY
3.1. Chapter Overview 3.8.2.4.2.1. Stirred-Tank Reactor Systems PLAYERS): COMPETITIVE LANDSCAPE
3.2. Viral and Non-Viral Methods of Gene Transfer 3.8.2.4.2.2. Fixed Bed Reactor / Packed Bed Reactor 6.1. Chapter Overview
3.3. Viral Vectors for Genetically Modified Therapies 3.8.2.4.2.3. WAVE Bioreactor System 6.2. Vector and Gene Therapy Manufacturers: Overall Market Landscape
3.4. Types of Viral Vectors 3.8.2.5. Serum-Containing versus Serum-Free Media 6.2.1. Analysis by Year of Establishment
3.4.1. Adeno-associated Viral Vectors 6.2.2. Analysis by Geographical Location of Manufacturing Facilities
3.4.2. Adenoviral Vectors 3.8.3. Bioprocessing of Viral Vectors 6.2.3. Analysis by Purpose of Production
3.4.3. Lentiviral Vectors 3.8.3.1. AAV Vector Production 6.2.4. Analysis by Scale of Production
3.4.4. Retroviral Vectors 3.8.3.2. Adenoviral Vector Production 6.2.5. Distribution by Application Area
3.4.5. Other Viral Vectors 3.8.3.3. Lentiviral Vector Production
3.4.5.1. Alphavirus 3.8.3.4. γ -Retroviral Vector Production 7 VECTOR AND GENE THERAPY MANUFACTURERS IN NORTH
3.4.5.2. Foamy Virus 3.8.4. Challenges Related to Vector Manufacturing AMERICA
3.4.5.3. Herpes Simplex Virus 7.1. Chapter Overview
3.4.5.4. Sendai Virus 3.9. Future of Vector Manufacturing 7.2. Aldevron
3.4.5.5. Simian Virus 7.2.1. Company Overview
3.4.5.6. Vaccinia Virus 4 VIRAL VECTOR AND GENE THERAPY MANUFACTURERS (INDUSTRY 7.2.2. Manufacturing Facilities
PLAYERS): COMPETITIVE LANDSCAPE 7.2.3. Manufacturing Experience
3.5. Types of Non-Viral Vectors 4.1. Chapter Overview 7.2.4. Future Outlook
3.5.1. Plasmid DNA 4.2. Viral Vector and Gene Therapy Manufacturers: Overall Market
3.5.2. Liposomes, Lipoplexes and Polyplexes Landscape 7.3. BioReliance / SAFC Commercial (Merck KGaA)
3.5.3. Oligonucleotides 4.2.1. Analysis by Year of Establishment 7.3.1. Company Overview
3.5.4. Other Non-Viral Vectors 4.2.2. Analysis by Company Size 7.3.2. Financial Information
3.5.5. Gene Delivery using Non-Viral Vectors 4.2.3. Analysis by Geographical Location of Headquarters 7.3.3. Vector Manufacturing Technology Portfolio
3.5.5.1. Biolistic Methods 4.2.4. Analysis by Geographical Location of Manufacturing Facilities 7.3.4. Manufacturing Facilities
3.5.5.2. Electroporation 4.2.5. Analysis by Type of Manufacturer 7.3.5. Future Outlook
3.5.5.3. Receptor Mediated Gene Delivery 4.2.6. Analysis by Purpose of Production
3.5.5.4. Gene Activated Matrix (GAM) 4.2.7. Analysis by Type of Vector 7.4. bluebird bio
4.2.8. Analysis by Scale of Production 7.4.1. Company Overview
3.6. Applications of Viral and Non-Viral Vectors
4.2.9. Analysis by Application Area 7.4.2. Financial Information
3.6.1. Type of Therapy
7.4.3. Manufacturing Facilities
3.6.1.1. Gene Therapy
5 PLASMID DNA AND GENE THERAPY MANUFACTURERS (INDUSTRY 7.4.4. Manufacturing Experience
3.6.1.2. Vaccinology
PLAYERS): COMPETITIVE LANDSCAPE 7.4.5. Future Outlook
3.7. Current Trends in Vector Development / Manufacturing 5.1. Chapter Overview
3.7.1. Vector Engineering 5.2. Plasmid DNA and Gene Therapy Manufacturers: Overall Market 7.5. Brammer Bio
3.7.2. Cargo Engineering Landscape 7.5.1. Company Overview
5.2.1. Analysis by Year of Establishment 7.5.2. Manufacturing Facilities
3.8. Vector Manufacturing 5.2.2. Analysis by Company Size 7.5.3. Manufacturing Experience 2019 © Roots Analysis
22
22
7.5.4. Future Outlook 8.3.1. Company Overview 8.9.6. Future Outlook
7.6. FUJIFILM Diosynth Biotechnologies 8.3.3. Future Outlook 8.10. Richter-Helm
7.6.1. Company Overview 8.10.1. Company Overview
7.6.2. Financial Information 8.4. Cobra Biologics 8.10.2. Manufacturing Facilities
7.6.3. Manufacturing Facilities 8.4.1. Company Overview 8.10.3. Future Outlook
7.6.4. Manufacturing Experience 8.4.2. Financial Performance
7.6.5. Future Outlook 8.4.3. Manufacturing Facilities 8.11. Sanofi (CEPiA, Sanofi Pasteur, Genzyme)
8.4.4. Vector Manufacturing Technology Portfolio 8.11.1. Company Overview
7.7. MassBiologics 8.4.5. Manufacturing Experience 8.11.2. Financial Information
7.7.1. Company Overview 8.4.6. Future Outlook 8.11.3. Manufacturing Facilities
7.7.2. Manufacturing Facilities 8.11.4. Manufacturing Experience
7.7.3. Future Outlook 8.5. FinVector 8.11.5. Future Outlook
8.5.1. Company Overview
7.8. Novasep 8.5.2. Manufacturing Facilities 8.12. uniQure
7.8.1. Company Overview 8.5.3. Viral Vector Manufacturing Technology 8.12.1. Company Overview
7.8.2. Financial Information 8.5.4. Future Outlook 8.12.2. Financial Information
7.8.3. Manufacturing Facilities 8.12.3. Manufacturing Facilities
7.8.4. Manufacturing Experience 8.6. Kaneka Eurogentec 8.12.4. Vector Manufacturing Technology Portfolio
7.8.5. Future Outlook 8.6.1. Company Overview 8.12.5. Future Outlook
7.9. Spark Therapeutics 8.6.3. Manufacturing Experience 8.13. VIVEbiotech
7.9.1. Company Overview 8.6.4. Future Outlook 8.13.1. Company Overview
7.9.2. Financial Information 8.13.2. Vector Manufacturing Technology Portfolio
7.9.3. Manufacturing Facilities 8.7. Lonza 8.13.3. Manufacturing Facilities
7.9.4. Vector Manufacturing Technology Portfolio 8.7.1. Company Overview 8.13.4. Future Outlook
7.9.5. Manufacturing Experience 8.7.2. Financial Information
7.9.6. Future Outlook 8.7.3. Vector Manufacturing Technology Portfolio 9 VECTOR AND GENE THERAPY MANUFACTURERS IN ASIA-PACIFIC
8.7.4. Manufacturing Facilities 9.1. Chapter Overview
7.10. Vigene Biosciences 8.7.5. Future Outlook 9.2. Wuxi AppTec
7.10.1. Company Overview 9.2.1. Company Overview
7.10.2. Manufacturing Facilities 8.8. MolMed 9.2.2. Financial Performance
7.10.3. Vector Manufacturing Technology Portfolio 8.8.1. Company Overview 9.2.3. Manufacturing Facilities
7.10.4. Manufacturing Experience 8.8.2. Financial Information 9.2.4. Manufacturing Experience
7.10.5. Future Outlook 8.8.3. Manufacturing Facilities 9.2.5. Future Outlook
8.8.4. Manufacturing Experience 9.3. Other Key Players
8 VECTOR AND GENE THERAPY MANUFACTURERS IN EUROPE 8.8.5. Future Outlook
8.1. Chapter Overview 10 EMERGING VECTORS
8.2. Biovian 8.9. Oxford BioMedica 10.1. Chapter Overview
8.2.1. Company Overview 8.9.1. Company Overview 10.1.1. Alphavirus Based Vectors
8.2.2. Manufacturing Facilities 8.9.2. Financial Information 10.1.2. Anc80 Based Vectors
8.2.3. Future Outlook 8.9.3. Manufacturing Facilities 10.1.3. Bifidobacterium longum Based Vectors
8.9.4. Vector Manufacturing Technology Portfolio 10.1.4. Cytomegalovirus Based Vectors
8.3. Cell and Gene Therapy Catapult 8.9.5. Manufacturing Experience 10.1.5. Listeria monocytogenes Based Vectors 2019 © Roots Analysis
23
23
10.1.6. Minicircle DNA Based Vectors Based Therapies 16 MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1.7. Modified Vaccinia Ankara Based Vectors 13.3. Viral Vector and Plasmid DNA Based Therapies: Pricing Models 16.1. Chapter Overview
10.1.8. Myxoma Virus Based Vectors 13.3.1. On the Basis of Expert Opinions 16.2. Scope of the Forecast
10.1.9. Self-Complementary Vectors 16.3. Input Tables and Key Assumptions
10.1.10. Sendai Virus Based Vectors 13.3.2. On the Basis of Manufacturing Cost 16.4. Forecast Methodology
10.1.11. Sleeping Beauty Transposons 13.3.2.1. On the Basis of Technology Used 16.5. Overall Viral Vector and Plasmid DNA Manufacturing Market, 2019-
13.3.2.2. On the Basis of Scale of Manufacturing 2030
11 RECENT COLLABORATIONS AND PARTNERSHIPS 13.3.2.3. On the Basis of Client Type 16.5.1. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030:
11.1. Chapter Overview 13.3.3. Prices of Different Types of Vectors Distribution by Type of Vector
11.2. Partnership Models 13.4. Concluding Remarks 16.5.1.1. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030:
11.3. Vector and Gene Therapy Manufacturing: Recent Collaborations and Market Attractiveness by Type of Vector
Partnerships 14 CAPACITY ANALYSIS 16.5.2. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030:
11.3.1. Analysis by Year of Partnership 14.1. Chapter Overview Distribution by Application Area
11.3.2. Analysis by Type of Partnership 14.2. Key Assumptions and Methodology 16.5.3. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030:
11.3.3. Analysis by Type of Vector 14.3. Installed, Global Viral Vector Manufacturing Capacity Distribution by Therapeutic Area
11.3.4. Analysis by Scale of Operation 14.3.1. Analysis by Company Size 16.5.4. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030:
11.3.5. Most Active Players: Analysis by Number of Partnerships 14.3.2. Analysis by Location of Manufacturing Facilities Distribution by Scale of Operation
11.3.6. Regional Analysis 14.3.3. Analysis by Scale of Operation 16.5.5. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030:
11.3.6.1. Most Active Players in Different Geographical Regions Distribution by Purpose of Production
11.3.6.2. Intercontinental and Intracontinental Agreements 14.4. Installed, Global Plasmid DNA Manufacturing Capacity 16.5.6. Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030:
11.4. Other Collaborations 14.4.1. Analysis by Company Size Distribution by Geography
14.4.2. Analysis by Location of Manufacturing Facilities
12 KEY INSIGHTS 14.4.3. Analysis by Scale of Operation 16.6. Current and Future Market Opportunity from Commercial Products
12.1. Chapter Overview 16.6.1. AAV Vectors
12.2. Vector and Gene Therapy Manufacturers: Analysis of Competitive 14.5. Installed, Global Viral Vector and Plasmid DNA Manufacturing 16.6.1.1. AAV Vector Manufacturing Market for Commercial Products, 2019-
Landscape by Purpose of Production, Type of Vector and Scale of Capacity 2030: Distribution by Application Area
Operation 14.6. Concluding Remarks 16.6.1.2. AAV Vector Manufacturing Market for Commercial Products, 2019-
12.3. Vector and Gene Therapy Manufacturers: Analysis by Company Size 2030: Distribution by Therapeutic Area
and Type of Vector 15 DEMAND ANALYSIS 16.6.1.3. AAV Vector Manufacturing Market for Commercial Products, 2019-
12.4. Vector and Gene Therapy Manufacturers: Prominent Geographical 15.1. Chapter Overview 2030: Distribution by Geography
Hubs by Type of Organization 15.2. Assumptions and Methodology
12.4.1. Contract Manufacturers 16.6.2. Adenoviral Vectors
12.4.2. In-House Manufacturers 15.3. Global, Clinical Demand for Viral Vector and Plasmid DNA 16.6.2.1. Adenoviral Vector Manufacturing Market for Commercial Products,
12.5. Vector and Gene Therapy Manufacturers: Analysis by Location of 15.3.1. Analysis by Geographical Location 2019-2030: Distribution by Application Area
Manufacturing Facilities and Type of Vector 15.3.2. Analysis by Type of Vector 16.6.2.2. Adenoviral Vector Manufacturing Market for Commercial Products,
12.5.1. AAV Vector Manufacturers 15.3.3. Analysis by Type of Therapy 2019-2030: Distribution by Therapeutic Area
12.5.2. Adenoviral Vector Manufacturers 16.6.2.3. Adenoviral Vector Manufacturing Market for Commercial Products,
12.5.3. Lentiviral Vector Manufacturers 15.4. Global, Commercial Demand for Viral Vector and Plasmid DNA 2019-2030: Distribution by Geography
12.5.4. Retroviral Vector Manufacturers 15.4.1. Analysis by Geographical Location
12.5.5. Plasmid DNA Manufacturers 15.4.2. Analysis by Type of Vector 16.6.3. Lentiviral Vectors
15.4.3. Analysis by Type of Therapy 16.6.3.1. Lentiviral Vector Manufacturing Market for Commercial Products,
13 VIRAL VECTOR AND PLASMID DNA COST PRICE ANALYSIS 2019-2030: Distribution by Application Area
13.1. Chapter Overview 15.5. Demand and Supply Analysis 16.6.3.2. Lentiviral Vector Manufacturing Market for Commercial Products,
13.2. Factors Contributing to High Price of Viral Vector and Plasmid DNA 15.6. Concluding Remarks 2019-2030: Distribution by Therapeutic Area 2019 © Roots Analysis
24
24
16.6.3.3. Lentiviral Vector Manufacturing Market for Commercial Products, 16.7.4. Retroviral Vectors 2019-2030: Distribution by Type of Animal Model Used
2019-2030: Distribution by Geography 16.7.4.1. Retroviral Vector Manufacturing Market for Clinical Candidates, 16.8.3.4. Lentiviral Vector Manufacturing Market for Preclinical Candidates,
2019-2030: Distribution by Application Area 2019-2030: Distribution by Geography
16.6.4. Retroviral Vectors 16.7.4.2. Retroviral Vector Manufacturing Market for Clinical Candidates,
16.6.4.1. Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Phase of Development 16.8.4. Retroviral Vectors
2019-2030: Distribution by Application Area 16.7.4.3. Retroviral Vector Manufacturing Market for Clinical Candidates, 16.8.4.1. Retroviral Vector Manufacturing Market for Preclinical Candidates,
16.6.4.2. Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography 2019-2030: Distribution by Application Area
2019-2030: Distribution by Therapeutic Area 16.8.4.2. Retroviral Vector Manufacturing Market for Preclinical Candidates,
16.6.4.3. Retroviral Vector Manufacturing Market for Commercial Products, 16.7.5. Plasmid DNA 2019-2030: Distribution by Therapeutic Area
2019-2030: Distribution by Geography 16.7.5.1. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 16.8.4.3. Retroviral Vector Manufacturing Market for Preclinical Candidates,
2019-2030: Distribution by Application Area 2019-2030: Distribution by Type of Animal Model Used
16.6.5. Plasmid DNA 16.7.5.2. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 16.8.4.4. Retroviral Vector Manufacturing Market for Preclinical Candidates,
16.6.5.1. Plasmid DNA Vector Manufacturing Market for Commercial 2019-2030: Distribution by Phase of Development 2019-2030: Distribution by Geography
Products, 2019-2030: Distribution by Application Area 16.7.5.3. Plasmid DNA Vector Manufacturing Market for Clinical Candidates,
16.8.5. Plasmid DNA
16.6.5.2. Plasmid DNA Vector Manufacturing Market for Commercial 2019-2030: Distribution by Geography
16.8.5.1. Plasmid DNA Manufacturing Market for Preclinical Candidates,
Products, 2019-2030: Distribution by Therapeutic Area 16.7.6. Other Viral and Non-Viral Vectors
2019-2030: Distribution by Application Area
16.6.5.3. Plasmid DNA Vector Manufacturing Market for Commercial
Products, 2019-2030: Distribution by Geography 16.8. Opportunity from Preclinical Candidates
2019-2030: Distribution by Therapeutic Area
16.6.6. Other Viral and Non-Viral Vectors 16.8.1. AAV Vectors
16.8.1.1. AAV Vector Manufacturing Market for Preclinical Candidates,
2019-2030: Distribution by Type of Animal Model Used
16.7. Opportunity from Clinical Candidates 2019-2030: Distribution by Application Area
16.7.1. AAV Vectors 16.8.1.2. AAV Vector Manufacturing Market for Preclinical Candidates,
2019-2030: Distribution by Geography
16.7.1.1. AAV Vector Manufacturing Market for Clinical Candidates, 2019- 2019-2030: Distribution by Therapeutic Area
16.8.6. Other Viral and Non-Viral Vectors
2030: Distribution by Application Area 16.8.8.3. AAV Vector Manufacturing Market for Preclinical Candidates,
16.7.1.2. AAV Vector Manufacturing Market for Clinical Products, 2019- 2019-2030: Distribution by Type of Animal Model Used 17 KEY DRIVERS AND CHALLENGES
2030: Distribution by Phase of Development 16.8.1.4. AAV Vector Manufacturing Market for Preclinical Candidates, 17.1. Chapter Overview
16.7.1.3. AAV Vector Manufacturing Market for Clinical Products, 2019- 2019-2030: Distribution by Geography 17.2. Viral Vector and Plasmid DNA Manufacturing Market: Drivers and
2030: Distribution by Geography Challenges
16.8.2. Adenoviral Vectors 17.2.1. AAV Vectors
16.7.2. Adenoviral Vectors 16.8.2.1. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 17.2.2. Adenoviral Vectors
16.7.2.1. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area 17.2.3. Lentiviral Vectors
2019-2030: Distribution by Application Area 16.8.2.2. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 17.2.4. Retroviral Vectors
16.7.2.2. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Therapeutic Area 17.2.5. Plasmid DNA
2019-2030: Distribution by Phase of Development 16.8.2.3. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 17.3. Concluding Remarks
16.7.2.3. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Type of Animal Model Used
2019-2030: Distribution by Geography 16.8.2.4. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 18 SURVEY ANALYSIS
2019-2030: Distribution by Geography 18.1. Chapter Overview
16.7.3. Lentiviral Vectors 18.2. Seniority Level of Respondents
16.7.3.1. Lentiviral Vector Manufacturing Market for Clinical Candidates, 16.8.3. Lentiviral Vectors 18.3. Type of Vector
2019-2030: Distribution by Application Area 16.8.3.1. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 18.4. Scale of Production
16.7.3.2. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area 18.5. Vector Stabilization Technology
2019-2030: Distribution by Phase of Development 16.8.3.2. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 18.6. In-house / Contract Operations
16.7.3.3. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Therapeutic Area
2019-2030: Distribution by Geography 16.8.3.3. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 19 CONCLUDING REMARKS 2019 © Roots Analysis
25
25
20 EXECUTIVE INSIGHTS 20.11.1. Company Snapshot
20.1. Chapter Overview 20.11.2. Interview Transcript: Alain Lamproye, President of Biopharma
20.2. Batavia Biosciences Business Unit
20.2.1. Company Snapshot
20.2.2. Interview Transcript: Menzo Havenga, Chief Executive Officer and 20.12. Richter-Helm
President 20.12.1. Company Snapshot
20.12.2. Interview Transcript: Astrid Brammer, Senior Manager Business
20.3. CEVEC Pharmaceuticals Development
20.3.2. Interview Transcript: Nicole Faust, Chief Executive Officer & Chief 20.13. Waisman Biomanufacturing
Scientific Officer 20.13.1. Company Snapshot
20.13.2. Interview Transcript: Brian M Dattilo, Business Development
20.4. Vigene Biosciences Manager
20.4.2. Interview Transcript: Jeffrey Hung, Chief Commercial Officer 20.14. Plasmid Factory
20.5. Clean Cells 20.14.2. Interview Transcript: Marco Schmeer, Project Manager and Tatjana
20.5.1. Company Snapshot Buchholz, Marketing Manager
20.5.2. Interview Transcript: Laurent Ciavatti, Business Development
Manager, Olivier Boisteau, Co-Founder / President and Xavier Leclerc, Head 20.15. GEG Tech
of Gene Therapy 20.15.1. Company Snapshot
20.15.2. Interview Transcript: Nicolas Grandchamp, R&D Leader
20.6. Amsterdam BioTherapeutics Unit (AmBTU)
21 APPENDIX I: TABULATED DATA
20.6.2. Interview Transcript: Joost van den Berg, Director
20.7. MGH Viral Vector Development Facility, Massachusetts General 22 APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Hospital
20.7.2. Interview Transcript: Bakhos A Tannous, Director
20.8. CJ PARTNERS
20.8.2. Interview Transcript: Interview Transcript, Colin Lee Novick,
Managing Director
20.9. Delphi Genetics

20.9.2. Interview Transcript: Cedric Szpirer, Executive & Scientific Director
20.10. ACGT
20.10.2. Interview Transcript: Semyon Rubinchik, Scientific Director
20.11. Novasep 2019 © Roots Analysis
26
26
List of Figures (1/3)
Figure 3.1 Gene Transfer: Viral and Non-Viral Methods Figure 7.3 bluebird bio: Revenues, 2014-2018 (USD Million)
Figure 3.2 Vector Manufacturing: Types of Manufacturers Figure 7.4 bluebird bio Viral Vectors: Stages of Manufacturing Process
Figure 3.3 Viral Vectors: Manufacturing Process Figure 7.5 FUJIFILM Holdings: Revenues, 2014-2018 (JPY Billion)
Figure 4.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Cumulative Trend by Year of Figure 7.6 Novasep: Revenues, 2013-2017 (EUR Million)
Establishment Figure 7.7 Novasep: Viral Vector Manufacturing Process
Figure 4.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size Figure 7.8 Spark Therapeutics: Revenues, 2014-2018 (USD Million)
Figure 4.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Figure 8.1 Lonza: Revenues, 2014- H1 2019 (CHF Million)
Location of Headquarters Figure 8.2 MolMed: Revenues, 2014-H1 2019 (EUR Million)
Figure 4.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Figure 8.3 Oxford BioMedica: Revenues, 2014-2018 (GBP Million)
Location of Manufacturing Facilities Figure 8.4 Sanofi: Revenues, 2014-H1 2019 (EUR Billion)
Figure 4.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Figure 8.5 uniQure: Revenues, 2014- 2018 (USD Million)
Manufacturer Figure 9.1 Wuxi Biologics: Revenues, 2014-H1 2019 (USD Million)
Figure 4.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Figure 11.1 Vector and Gene Therapy Partnerships: Cumulative Year-wise Trend (2015–2019)
Production (In-house Production versus Contract Manufacturing Services) Figure 11.2 Vector and Gene Therapy Partnerships: Distribution by Type
Figure 4.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector Figure 11.3 Vector and Gene Therapy Partnerships: Distribution by Type of Vector
Figure 4.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Figure 11.4 Vector and Gene Therapy Partnerships: Distribution by Scale of Operation
Production Figure 11.5 Vector and Gene Therapy Partnerships: Most Active Players
Figure 4.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area Figure 11.6 Vector and Gene Therapy Partnerships: Regional Distribution and Most Active Players
Figure 5.1 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Cumulative Trend by Year of Figure 11.7 Vector and Gene Therapy Partnerships: Regional Distribution by Intercontinental and
Establishment Intracontinental Agreements
Figure 5.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size Figure 12.1 Vector and Gene Therapy Manufacturers: Competitive Landscape by Purpose of Production,
Figure 5.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Type of Vector and Scale of Operation
Location of Headquarters Figure 12.2 Vector and Gene Therapy Manufacturers: Logo Landscape by Company Size and Type of
Figure 5.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Vector
Location of Manufacturing Facilities Figure 12.3 Vector and Gene Therapy Contract Manufacturers: Prominent Geographical Hubs
Figure 5.5 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Figure 12.4 Vector and Gene Therapy In-House Manufacturers: Prominent Geographical Hubs
Manufacturer Figure 12.5 AAV Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 5.6 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Figure 12.6 Adenoviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Production (In-house Production versus Contract Manufacturing Services) Figure 12.7 Lentiviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 5.7 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Figure 12.8 Retroviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Production Figure 12.9 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 5.8 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Figure 14.1 Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample
Area Data Set)
Figure 6.1 Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Figure 14.2 Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample
Establishment Data Set)
Figure 6.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Figure 14.3 Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size
Manufacturing Facilities Figure 14.4 Installed, Global Viral Vector Manufacturing Capacity: Distribution by Range of Installed
Figure 6.5 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Purpose of Capacity
Production (In-house Production versus Contract Manufacturing Services) Figure 14.5 Installed, Global Viral Vector Manufacturing Capacity: Distribution by Geographical Location of
Figure 6.6 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Manufacturing Facilities
Production Figure 14.6 Installed, Global Viral Vector Manufacturing Capacity: Distribution by Scale of Operation
Figure 6.7 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area Figure 14.7 Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size
Figure 7.1 SAFC Commercial: Revenues, 2011- Q3 2015 (USD Million) Figure 14.8 Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed
Figure 7.2 H.A.V.E.: AAV Vector Manufacturing Technology Capacity 2019 © Roots Analysis
27
27
Figure 14.9 Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Location of Manufacturing Application Area (USD Million)
Facilities Figure 16.16 Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by
Figure 14.10 Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Scale of Operation Therapeutic Area (USD Million)
Figure 14.11 Installed, Global Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Figure 16.17 Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by
Geographical Location of Manufacturing Facilities Geography (USD Million)
Figure 14.12 Installed, Global Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Figure 16.18 Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by
Vector Application Area (USD Million)
Figure 15.1. Global Clinical Demand for Viral Vector and Plasmid DNA Figure 16.19 Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by
Figure 15.2. Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location Therapeutic Area (USD Million)
Figure 15.3. Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Figure 16.20 Retroviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by
Figure 15.4. Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy Geography (USD Million)
Figure 15.5. Global Commercial Demand for Viral Vector and Plasmid DNA Figure 16.21 Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution
Figure 15.6. Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location by Application Area (USD Million)
Figure 15.7. Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Figure 16.22 Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution
Figure 15.8. Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy by Therapeutic Area (USD Million)
Figure 15.9. Demand and Supply Distribution Figure 16.23 Plasmid DNA Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution
Figure 16.1 Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030 (USD Billion) by Geography (USD Million)
Figure 16.2 Viral Vector and Plasmid DNA Manufacturing, 2019-2030: Distribution by Type of Vector (USD Figure 16.24 Other Vector Manufacturing Market for Commercial Products, 2019-2030 (USD Million)
Million) Figure 16.25 AAV Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Figure 16.3 Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Market Attractiveness Analysis Application Area (USD Million)
by Type of Vector Figure 16.26 AAV Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase
Figure 16.4 Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Application Area of Development (USD Million)
(USD Million) Figure 16.27 AAV Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Figure 16.5 Viral Vector and Plasmid DNA Manufacturing Market, 2020, 2025 and 2030: Distribution by Geography (USD Million)
Therapeutic Area (USD Million) Figure 16.28 Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Figure 16.6 Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Scale of Application Area (USD Million)
Operation (USD Million) Figure 16.29 Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Figure 16.7 Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Purpose of Phase of Development (USD Million)
Production (USD Million) Figure 16.30 Adenoviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Figure 16.8 Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Geography Geography (USD Million)
(USD Million) Figure 16.31 Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Figure 16.9 AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million)
Application Area (USD Million) Figure 16.32 Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Figure 16.10 AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Phase of Development (USD Million)
Therapeutic Area (USD Million) Figure 16.33 Lentiviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Figure 16.11 AAV Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
Geography (USD Million) Figure 16.34 Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Figure 16.12 Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million)
Application Area (USD Million) Figure 16.35 Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Figure 16.13 Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Phase of Development (USD Million)
Therapeutic Area (USD Million) Figure 16.36 Retroviral Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Figure 16.14 Adenoviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
Geography (USD Million) Figure 16.37 Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution
Figure 16.15 Lentiviral Vector Manufacturing Market for Commercial Products, 2019-2030: Distribution by by Application Area (USD Million) 2019 © Roots Analysis
28
28
Figure 16.38 Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
Phase of Development (USD Million) Figure 16.61 Other Vectors Manufacturing Market for Preclinical Candidates, 2019-2030 (USD Million)
Figure 16.39 Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Figure 17.1 AAV Vectors: Drivers and Challenges
Geography (USD Million) Figure 17.2 Adenoviral Vectors: Drivers and Challenges
Figure 16.40 Other Vector Manufacturing Market for Clinical Candidates, 2019-2030 (USD Million) Figure 17.3 Lentiviral Vectors: Drivers and Challenges
Figure 16.41 AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Figure 17.4 Retroviral Vectors: Drivers and Challenges
Application Area (USD Million) Figure 17.5 Plasmid DNA: Drivers and Challenges
Figure 16.42 AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Figure 18.1 Survey Analysis: Distribution by Type of Organization
Therapeutic Area (USD Million) Figure 18.2 Survey Analysis: Distribution by Geographical Location of Organization
Figure 16.43 AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of Figure 18.3 Survey Analysis: Distribution by Seniority Level of Respondents
Animal Model Used (USD Million) Figure 18.4 Survey Analysis: Distribution by Type of Vector
Figure 16.44 AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Figure 18.5 Survey Analysis: Distribution by Scale of Production
Geography (USD Million) Figure 18.6 Survey Analysis: Vector Stabilization Technology
Figure 16.45 Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Figure 18.7 Survey Analysis: Distribution by Purpose of Production (In-house Production versus Contract
Application Area (USD Million) Services)
Figure 16.46 Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Therapeutic Area (USD Million)
Type of Animal Model Used (USD Million)
Geography (USD Million)
Figure 16.49 Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Application Area (USD Million)
Figure 16.53 Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Figure 16.57 Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Figure 16.58 Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Therapeutic Area USD Million)
Figure 16.59 Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type
of Animal Model Used (USD Million)
Figure 16.60 Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by 2019 © Roots Analysis
29
29
List of Tables (1/4)
Table 3.1 Viral Vectors: Key Features Table 11.1 Vector and Gene Therapy Manufacturing: List of Partnerships
Table 3.2 Small Scale Cell Culture Systems Table 11.2 Vector and Gene Therapy Manufacturing Partnerships: Most Active Players
Table 4.1 Viral Vector and Gene Therapy Manufacturers: List of Industry Players Table 11.3 Vector and Gene Therapy Manufacturing: List of Other Partnerships
Table 4.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Type of Viral Table 13.1 Viral Vector and Plasmid DNA Cost Price Analysis: Expert Opinions / Primary Research
Vector Table 13.2 Viral Vector and Plasmid DNA: Prices of Vectors
Table 4.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Scale of Table 14.1 Installed, Global Viral Vector Manufacturing Capacity: Sample Data Set
Production Table 14.2 Installed, Global Plasmid DNA Manufacturing Capacity: Sample Data Set
Table 4.4. Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Application Area Table 14.3 Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size
Table 5.1 Plasmid DNA and Gene Therapy Manufacturers: List of Industry Players Table 14.4 Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size
Table 5.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Scale of Table 15.1. Demand Analysis: List of Approved Cell and Gene Therapies
Production Table 16.1 Viral Vector and Plasmid DNA: Active Clinical Studies
Table 5.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Application Area Table 16.2 Viral Vector and Plasmid DNA: Distribution by Patients Enrolled in the Active Clinical Studies
Table 6.1 Vector and Gene Therapy Manufacturers: List of Non-Industry Players Table 16.3 Viral Vector and Plasmid DNA: Number of Active Clinical Trials, 2019-2030
Table 6.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Scale of Table 16.4 Viral Vector and Plasmid DNA: Number of Patients Enrolled in Active Clinical Trials, 2019-2030
Production Table 16.5 Viral Vector and Plasmid DNA: Approved / Late-Stage Genetically Modified Therapies
Table 6.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Application Area Table 18.1 Survey Response: Overview of the Participating Companies / Organizations
Table 7.1 Vector and Gene Therapy Production in North America: List of Profiled Companies Table 18.2 Survey Response: Seniority Level of Respondents
Table 7.2 Aldevron Plasmid DNA: QC Assays Table 18.3 Survey Response: Type of Vector
Table 7.3. Aldevron: Future Outlook Table 18.4 Survey Response: Scale of Production
Table 7.4. BioReliance / SAFC Commercial (Merck KGaA): Future Outlook Table 18.5 Survey Response: Vector Stabilization Technology
Table 7.5 bluebird bio: Future Outlook Table 18.6 Survey Response: Purpose of Production (In-house Production versus Contract Services)
Table 7.6 Brammer Bio: Future Outlook Table 20.1 CEVEC Pharmaceuticals: Key Highlights
Table 7.7 FUJIFILM Diosynth Biotechnologies: Future Outlook Table 20.2 Clean Cells: Key Highlights
Table 7.8 MassBiologics: Future Outlook Table 20.3 Amsterdam BioTherapeutics Unit (AmBTU): Key Highlights
Table 7.9 Novasep Viral Vectors: Manufacturing Experience Table 20.4 MGH Viral Vector Development Facility, Massachusetts General Hospital: Key Highlights
Table 7.10 Novasep: Future Outlook Table 20.5 CJ PARTNERS Key Highlights
Table 7.11 Spark Therapeutics: Future Outlook Table 20.6 Delphi Genetics: Key Highlights
Table 7.12 Vigene Biosciences: Future Outlook Table 20.7 ACGT: Key Highlights
Table 8.1 Vector and Gene Therapy Production in Europe: List of Players Profiled Table 20.8 Waisman Biomanufacturing: Key Highlights
Table 8.2 Biovian: Future Outlook Table 20.9 PlasmidFactory: Key Highlights
Table 8.3 Cell and Gene Therapy Catapult: Future Outlook Table 20.10 GEG Tech: Key Highlights
Table 8.4 Cobra Biologics: Future Outlook Table 21.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Cumulative Trend by Year of
Table 8.5 FinVector Manufacturing Suites: Features Establishment
Table 8.6 FinVector: Future Outlook Table 21.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 8.7 Kaneka Eurogentec: Future Outlook Table 21.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical
Table 8.8 Lonza: Future Outlook Location of Headquarters
Table 8.9 MolMed: Future Outlook Table 21.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical
Table 8.10 Oxford BioMedica: Future Outlook Location of Manufacturing Facilities
Table 8.11 Richter-Helm: Future Outlook Table 21.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of
Table 8.12 Sanofi (CEPiA, Sanofi Pasteur, Genzyme): Future Outlook Manufacturer
Table 8.13 uniQure: Future Outlook Table 21.5 Viral Vector Manufacturers and Gene Therapy Manufacturers (Industry Players): Distribution by
Table 8.14 VIVEbiotech: Future Outlook Purpose of Production (In-house Production versus Contract Manufacturing Services)
Table 9.1 Vector and Gene Therapy Manufacturers: List of Key Players based in Asia Pacific Table 21.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector
Table 9.2 Wuxi AppTec: Future Outlook Table 21.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale2019of © Roots Analysis
30
30
Production Table 21.38 Vector and Gene Therapy Partnerships: Regional Distribution by Intercontinental and
Table 21.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area Intracontinental Agreements
Table 21.9 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Cumulative Trend by Year of Table 21.39 Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample
Establishment Data Set)
Table 21.10 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Table 21.40 Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample
Size Data Set)
Table 21.10 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Table 21.41 Installed, Global Viral Vector Manufacturing Capacity: Distribution by Company Size
Location of Headquarters Table 21.42 Installed, Global Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity
Table 21.11 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Table 21.42 Installed, Global Viral Vector Manufacturing Capacity: Distribution by Geographical Location of
Location of Manufacturing Facilities Manufacturing Facilities
Table 21.12 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Table 21.43 Installed, Global Viral Vector Manufacturing Capacity: Distribution by Scale of Operation
Manufacturer Table 21.45 Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Company Size
Table 21.13 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Purpose of Table 21.46 Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed
Production (In-house Production versus Contract Manufacturing Services) Capacity
Table 21.14 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Table 21.47 Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Geographical Location of
Production Manufacturing Facilities
Table 21.15 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Table 21.48 Installed, Global Plasmid DNA Manufacturing Capacity: Distribution by Scale of Operation
Area Table 21.49 Installed, Global Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of
Table 21.16 Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Vector
Establishment Table 21.50 Global Clinical Demand for Viral Vector and Plasmid DNA
Table 21.17 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Geographical Table 21.51 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location
Location of Manufacturing Facilities Table 21.52 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector
Table 21.18 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Purpose of Table 21.53 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy
Production (In-house Production versus Contract Manufacturing Services) Table 21.54 Global Commercial Demand for Viral Vector and Plasmid DNA
Table 21.19 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Table 21.55 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location
Production Table 21.56 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector
Table 21.20 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area Table 21.57 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy
Table 21.21 SAFC: Revenues, 2011-Q3 2015 (USD Million) Table 21.58 Demand and Supply Distribution
Table 21.22 bluebird bio: Revenues, 2014-2018 (USD Million) Table 21.59 Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030 (USD Billion)
Table 21.23 FUJIFILM Holdings: Revenues, 2014-2018(JPY Billion) Table 21.60 Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Type of Vector
Table 21.24 Novasep: Revenues, 2013-2017 (EUR Million) (USD Million)
Table 21.25 Spark Therapeutics: Revenues, 2014-2018 (USD Million) Table 21.61 Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Application
Table 21.26 Lonza: Revenues, 2014-H1 2019 (CHF Million) Area (USD Million)
Table 21.27 MolMed: Revenues, 2014-H1 2019 (EUR Million) Table 21.62 Viral Vector and Plasmid DNA Manufacturing Market, 2020, 2025 and 2030: Distribution by
Table 21.28 Oxford BioMedica: Revenues, 2014-2018 (GBP Million) Therapeutic Area (USD Million)
Table 21.29 Sanofi: Revenues, 2014-H1 2019 (EUR Billion) Table 21.63 Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Scale of
Table 21.30 uniQure: Revenues, 2014-2018 (USD Million) Operation (USD Million)
Table 21.31 Wuxi Biologics: Revenues, 2014-H1 2019 (USD Million) Table 21.64 Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Purpose of
Table 21.32 Vector and Gene Therapy Partnerships: Cumulative Year-wise Trend (2015- 2019) Production (USD Million)
Table 21.33 Vector and Gene Therapy Partnerships: Distribution by Type Table 21.65 Viral Vector and Plasmid DNA Manufacturing Market, 2019-2030: Distribution by Geography
Table 21.34 Vector and Gene Therapy Partnerships: Distribution by Type of Vector (USD Million)
Table 21.35 Vector and Gene Therapy Partnerships: Distribution by Scale of Operation Table 21.66 AAV Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by
Table 21.36 Vector and Gene Therapy Partnerships: Most Active Players Application Area (USD Million)
Table 21.37 Vector and Gene Therapy Partnerships: Regional Distribution and Most Active Players Table 21.67 AAV Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution2019 by © Roots Analysis
31
31
Therapeutic Area (USD Million) Table 21.90 Lentiviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Table 21.68 AAV Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
Geography (USD Million) Table 21.91 Retroviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Table 21.69 Adenoviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million)
Application Area (USD Million) Table 21.92 Retroviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Table 21.70 Adenoviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Phase of Development (USD Million)
Therapeutic Area (USD Million) Table 21.93 Retroviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Table 21.71 Adenoviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
Geography (USD Million) Table 21.94 Plasmid DNA Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Table 21.72 Lentiviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Application Area (USD Million)
Application Area (USD Million) Table 21.95 Plasmid DNA Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Table 21.73 Lentiviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Phase of Development (USD Million)
Therapeutic Area (USD Million) Table 21.96 Plasmid DNA Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by
Table 21.74 Lentiviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Geography (USD Million)
Geography (USD Million) Table 21.97 Other Viral Vectors Manufacturing Market for Clinical Candidates, 2019-2030 (USD Million)
Table 21.75 Retroviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Table 21.98 AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Application Area (USD Million) Application Area (USD Million)
Table 21.76 Retroviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Table 21.99 AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Therapeutic Area (USD Million) Therapeutic Area (USD Million)
Table 21.77 Retroviral Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Table 21.100 AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of
Geography (USD Million) Animal Model Used (USD Million)
Table 21.78 Plasmid DNA Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Table 21.101 AAV Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Application Area (USD Million) Geography (USD Million)
Table 21.79 Plasmid DNA Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Table 21.102 Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Therapeutic Area (USD Million) Application Area (USD Million)
Table 21.80 Plasmid DNA Vectors Manufacturing Market for Commercial Products, 2019-2030: Distribution by Table 21.103 Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Geography (USD Million) Therapeutic Area (USD Million)
Table 21.81 Other Viral Vector Manufacturing Market for Commercial Products, 2019-2030 (USD Million) Table 21.104 Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Table 21.82 AAV Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Type of Animal Model Used (USD Million)
Area (USD Million) Table 21.105 Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Table 21.83 AAV Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase of Geography (USD Million)
Development (USD Million) Table 21.106 Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Table 21.84 AAV Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography Application Area (USD Million)
(USD Million) Table 21.107 Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Table 21.85 Adenoviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Therapeutic Area (USD Million)
Application Area (USD Million) Table 21.108 Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Table 21.86 Adenoviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase Type of Animal Model Used (USD Million)
of Development (USD Million) Table 21.109 Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Table 21.87 Adenoviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Geography (USD Million)
Geography (USD Million) Table 21.110 Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Table 21.88 Lentiviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Application Area (USD Million)
Application Area (USD Million) Table 21.111 Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Table 21.89 Lentiviral Vectors Manufacturing Market for Clinical Candidates, 2019-2030: Distribution by Phase Therapeutic Area (USD Million)
of Development (USD Million) Table 21.112 Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution
2019 ©by
Roots Analysis
32
32
Table 21.113 Retroviral Vector Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Table 21.114 Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by
Table 21.116 Plasmid DNA Manufacturing Market for Preclinical Candidates, 2019-2030: Distribution by Type of
Animal Model Used (USD Million)
Table 21.118 Other Vector Manufacturing Market for Preclinical Candidates, 2019-2030 (USD Million)
Table 21.119 Survey Analysis: Distribution by Type of Organization
Table 21.120 Survey Analysis: Distribution by Geographical Location of Organization
Table 21.121 Survey Analysis: Distribution by Seniority Level of Respondents
Table 21.122 Survey Analysis: Distribution by Type of Vector
Table 21.123 Survey Analysis: Distribution by Scale of Production
Table 21.124 Survey Analysis: Vector Stabilization Technology
Table 21.125 Survey Analysis: Distribution by Purpose of Production (In-house Production versus Contract
Services)
33
33
List of Companies and Organizations (1/3)
1. 4D Molecular Therapeutics 44. Baxter Memorial Sloan Kettering Cancer Center 116. Eurofins Genomics
2. AbbVie 45. Beckman Research Institute 81. Celladon 117. Eurofins Scientific
3. Abeona Therapeutics 46. Belfer Gene Therapy Core Facility, Cornell 82. Cellectis 118. European Society of Gene and Cell Therapy
4. Acucela University 83. Cellular Biomedicine Group 119. ExcellGene
5. Adaptimmune Therapeutics 47. Belfer Gene Therapy Core Facility, Cornell 84. Celonic 120. Finnish Bioindustries
6. Addgene University 85. Center for Biomedicine & Genetics, City of Hope 121. FinVector (previously known as Ark Therapeutics)
7. Aduro Biotech 48. Benitec Biopharma 86. Center for Cell & Gene Therapy, Baylor College of 122. Fisher BioServices
8. Advanced BioScience Laboratories (ABL) 49. BioCancell Medicine 123. Five Prime Therapeutics
9. Advanced Biotherapeutics Consulting 50. Biogen 87. Center for Cell and Gene Processing, Takara Bio 124. FKD Therapies
10. Advaxis 51. Biomay 88. Centre for Cell and Vector Production, Centre for 125. Flash Therapeutics
11. ADVENT 52. Biomiga Commercialization of Regenerative Medicine 126. Florida Biologix
12. Adverum Biotechnologies (previously known as 53. BioNTech Innovative Manufacturing Service 89. CEVEC Pharmaceuticals 127. Fondazione Telethon
Avalanche Biotechnologies) (previously known as Eufects) 90. Chiesi Farmaceutici 128. Foundation Fighting Blindness
13. Agenzia Italiana del Farmaco 54. BioReliance 91. Children's GMP, St. Jude Children's Research 129. Fraunhofer Institute for Toxicology and
14. Agilent Technologies 55. Biotec Services International Hospital Experimental Medicine
15. Agilis Biotherapeutics 56. Biotechnology Department of San Raffaele 92. Children's Hospital of Philadelphia 130. Freeline Therapeutics
16. Aldevron 57. Biotherapeutics Development Unit, Cancer 93. CIEMAT 131. FUJIFILM Diosynth Biotechnologies
17. Allele Biotechnology Research UK 94. Cincinnati Children's Hospital Medical Center 132. GE Healthcare
18. Alma Bio Therapeutics 58. Biotie Therapies 95. Clean Cells 133. GEG Tech
19. AlphaVax 59. Bioverativ 96. Clinical Biotechnology Centre, NHS Blood and 134. Genable Technologies
20. Althea Technologies 60. BioVex Transplant 135. Gene and Cell Therapy Lab, Institute of
21. American Gene Technologies 61. Biovian 97. Clinical Vector Production Core, University of Translational Health Sciences
22. Amgen 62. Blue Sky BioServices Pittsburgh 136. Gene Editing and Viral Vector Core, City of Hope
23. AMSBIO 63. Bluebird Bio (previously known as Genetix 98. Cobra Biologics 137. Gene Editing and Viral Vector Core, City of Hope
24. Amsterdam BioTherapeutics Unit (AmBTU) Pharmaceuticals) 99. CombiGene 138. Gene Medicine Japan
25. Anaeropharma Science 64. B-MoGen Biotechnologies 100. Core Facility for Therapeutic Vectors, Institute of 139. Gene Silencing and Expression Facility, Robinson
26. Anemocyte 65. Boehringer Ingelheim BioXcellence™ Medical Science Research Hospital Research Institute, University of Adelaide
27. apceth Biopharma 66. Brammer Bio (now a part of Thermo Fisher 101. Cranfield University 140. Gene Therapy Clinical Vector Production Core,
28. Applied Biological Materials (ABM) Scientific) 102. Creative Biogene University of Pittsburgh
29. Applied Genetic Technologies (AGTC) 67. Brazilian Biosciences National Laboratory (LNBio) 103. Creative Biolabs 141. Gene Therapy Research Institute
30. Applied Viromics 68. BRC Clinical Research Facility and Cell Therapy 104. Creed Commercial Development 142. Gene Transfer Vector Core, Grousbeck Gene
31. ARCO Design/Build Unit, King's College London 105. Cytovance Biologics Therapy Center
32. Areta International 69. Brewin Dolphin 106. Deerfield Management 143. Gene Transfer Vector Core, Schepens Eye
33. Asklepios BioPharmaceutical 70. Bristol-Myers Squibb 107. Delphi Genetics Research Institute
34. Atlantic Bio GMP 71. Brookside Capital 108. Department of Neuroscience, University of 144. Gene Transfer, Targeting and Therapeutics Core,
35. ATVIO Biotech 72. California Institute for Regenerative Medicine Minnesota Salk Institute for Biological Studies
36. Audentes Therapeutics 73. California Institute of Technology 109. Desktop Genetics 145. GeneCure Biotechnologies
37. Autolus 74. Calimmune 110. Division of Human Gene Therapy, Stanford 146. GeneDetect
38. AveXis 75. Cancer Research UK University 147. GeneImmune Biotechnology
39. Avista Capital Partners 76. Capsugel 111. DNAtrix 148. Genethon
40. AVROBIO 77. Carnegie Institution for Science 112. Elixirgen Scientific 149. GENEWIZ
41. Bamboo Therapeutics 78. Celgene 113. Emergent BioSolutions 150. GenIbet Biopharmaceuticals
42. Batavia Biosciences 79. Cell and Gene Therapy Catapult 114. Epeius Biotechnologies 151. GenScript
43. Bavarian Nordic 80. Cell Therapy and Cell Engineering Facility, 115. EUFETS 152. GenVec 2019 © Roots Analysis
34
34
153. Genzyme 193. Luminous BioSciences 230. Ocular Gene Therapy Core, National Eye Institute 272. SIRION Biotech
154. GIGA Institute, Liege Universite 194. Lund University 231. Okairos 273. Sofinnova Ventures
155. Gilead Sciences 195. Lysogene 232. Omnia Biologics 274. Spark Therapeutics
156. GlaxoSmithKline 196. Massachusetts Eye and Ear 233. Orchard Therapeutics 275. St Thomas' NHS Foundation Trust
157. Green Cross LabCell 197. Massachusetts Life Science Center 234. Oxford BioMedica 276. Stevenage Bioscience Catalyst
158. Guy's Hospital, London 198. MassBiologics 235. Oxford Genetics 277. Strathmann Biotec
159. Hercules Capital 199. MaxCyte 236. PacificGMP 278. Stratophase
160. Hong Kong Institute of Biotechnology 200. Medigene 237. Paragon Gene Therapy, Catalent Biologics 279. Synpromics
161. Hookipa Biotech 201. MeiraGTx 238. Penn Vector Core, University of Pennsylvania 280. Synthace
162. Hope Center Viral Vectors Core, Washington University 202. Merck 239. Pfizer 281. Synthetic Genomics
School of Medicine 203. Merck Serono 240. PharmaChem Technologies 282. System Biosciences
163. Horizon Discovery 204. Merial 241. Pinchal & Company 283. T. Rowe Price Associates
164. Hospital de Sant Pau 205. Michael J. Fox Foundation for Parkinson Research 242. PlasmidFactory 284. Tecrea
165. Human Gene and Cell Therapy Center, Akdeniz 206. Mila's Miracle Foundation 243. Powell Gene Therapy Center, University of Florida 285. Terry Fox Laboratory
University 207. MilliporeSigma 244. Precigen 286. Texas A&M University
166. Human Stem Cells Institute 208. Ministry of Economy and Competitiveness 245. ProBioGen 287. The Finnish Fair Foundation
167. ID Pharma (previously known as DNAVEC) 209. Mitsubishi 246. ProMab Biotechnologies 288. The Goldyne Savad Institute of Gene Therapy,
168. Immune Design 210. Molecular Diagnostic Services 247. Protein Sciences Hadassah Medical Organization
169. Immune Technology 211. Molecular Virology Core, Oregon National Primate 248. Provecs Medical 289. The Jarvis Lab
170. ImmunoGenes Research Center, Oregon Health & Science 249. Puresyn 290. The Wellcome Trust
171. Immunomic Therapeutics University 250. Raymond G. Perelman Center for Cellular and 291. The Wellcome Trust / BRC Clinical Research
172. Inbiomed 212. MolMed Molecular Therapeutics, Children's Hospital of Facility and Cell Therapy Unit (CTU), King’s
173. Indiana University Vector Production Facility 213. Myeloma Crowd Research Initiative Philadelphia College London
174. Instituto de Tecnologia Química e Biológica António 214. NanoCor Therapeutics 251. Rayne Cell Therapy Suite, King's College London 292. TheraBiologics
Xavier 215. Nantes Gene Therapy Institute 252. REGENXBIO 293. THERAVECTYS
175. Intrexon 216. National Cancer Institute 253. Renova Therapeutics 294. Therexsys
176. InvivoGen 217. National Center for Advancing Translational 254. Richter-Helm BioLogics 295. Thermo Fisher Scientific
177. IPPOX Foundation Sciences 255. RIKEN BioResource Research Center 296. TissueGene
178. IQVIA Stem Cell Center 218. National Human Genome Research Institute 256. Roche 297. Touchlight Genetics
179. Janelia Research Campus 219. National Institute of Neurodegenerative Disorders 257. Rock Springs Capital 298. Transgene
180. Janssen and Stroke Center Core, University of Minnesota 258. Rocket Pharmaceuticals 299. Treeway
181. Kalon Biotherapeutics 220. National Institutes of Health 259. SAB-Technology 300. Twist Bioscience
182. Kaneka Eurogentec 221. National Virus Vector Laboratory, University of 260. SAFC 301. TxCell
183. Kelley School of Business, Indiana University Eastern Finland 261. Sanofi CEPiA 302. UAB Vector Production Facility
184. King's College London, Guy's and St Thomas' NHS 222. Nature Technology 262. Sanofi Genzyme 303. uniQure
Foundation Trust 223. Naval Medical Research Center 263. Sanofi Pasteur 304. Unit Biotech & ATMP’s, University Medical Center
185. Kite Pharma 224. Neuroscience CenterVector Core, Massachusetts 264. Sartorius Stedim Biotech Groningen
186. Kobe Biomedical Innovation Cluster General Hospital 265. Scancell 305. UniTech Pharma
187. Kolon Life Sciences 225. Neuroscience Gene Vector and Virus Core, 266. Selecta Biosciences 306. University of Florida
188. Laboratory of Malaria Immunology and Vaccinology Stanford Medicine 267. Shanghai Sunway Biotech 307. University of Iowa Research Foundation
189. Lentigen Technology 226. NewLink Genetics 268. Shenzhen SiBiono GeneTech 308. University of Liège
190. Lentiviral Lab, USC School of Pharmacy 227. Nikon CeLL innovation 269. SignaGen Laboratories 309. University of Massachusetts Medical School
191. Leuven Viral Vector Core 228. Novartis 270. SillaJen System
192. Lonza 229. Novasep 271. Sino Biological 310. University of Oxford Clinical BioManufacturing
35
35
Facility Dscovery Institute
311. University of Virginia School of Medicine 345. Viral Vector Core, The Jackson Laboratory
312. Vaccibody 346. Viral Vector Core, The Jenner Institute
313. Vaccine and Gene Therapy Institute 347. Viral Vector Core, University of Massachusetts
314. Valneva Medical School
315. VBI Vaccine 348. Viral Vector Core, University of South Carolina
316. Vectalys School of Medicine
317. Vector Biolabs 349. Viral Vector Facility, Neuroscience Center Zurich
318. Vector Core / GMP Facility, UC Davis Health 350. Viral Vector Production Laboratory, Mayo Clinic
319. Vector Core Laboratory, Powell Gene Therapy Center, Cancer Center
University of Florida 351. Viral Vector Production Unit, Universitat Autònoma
320. Vector Core of Gene Therapy, Laboratory of Nantes de Barcelona-Vall d'Hebrón Institut de Recerca
321. Vector Core, Harvard Gene Therapy Initiative 352. Viral Vectors Laboratory, Louisiana State
322. Vector Core, Telethon Institute of Genetics and University School of Veterinary Medicine
Medicine 353. ViralGEN
323. Vector Core, University of Michigan Medical School 354. ViroMed
324. Vector Core, University of North Carolina 355. Virovek
325. Vector Development and Production Facility, Roswell 356. VirusTech Core Facility, Karolinska Institutet
Park Comprehensive Cancer Center 357. Vivante GMP Solutions
326. Vector Development Core Laboratory, UC San Diego 358. VIVEbiotech
School of Medicine 359. Voyager Therapeutics
327. Vector Production Facility, Indiana University 360. Waisman Biomanufacturing
328. Vecura GMP Laboratory, Karolinska Institutet 361. Weber Laboratory, Icahn School of Medicine at
329. VGXI Mount Sinai
330. Vibalogics 362. Wellington Management
331. Vical 363. West Biotherapy (also known as EFS Atlantic Bio
332. Vigene Biosciences GMP)
333. Viral Core Facility, NeuroCure 364. Wolfson Gene Therapy Unit, University College of
334. Viral Core, Seattle Children's Research Institute London
335. Viral Gene Transfer Core, Massachusetts Institute of 365. WuXi AppTec
Technology 366. Xpress Biologics
336. Viral Vector and Cloning Core, University of Minnesota 367. Yposkesi
337. Viral Vector Core / Clinical Manufacturing Facility, 368. Ziopharm Oncology
Nationwide Children's Hospital
338. Viral Vector Core Facility, University of Iowa Carver
College of Medicine
339. Viral Vector Core Laboratory, National Institute of
Environmental Health Sciences
340. Viral Vector Core Laboratory, The University of
Tennessee Health Science Center
341. Viral Vector Core, Duke University
342. Viral Vector Core, Emory University School of Medicine
343. Viral Vector Core, Maine Medical Research Institute
344. Viral Vector Core, Sanford Burnham Prebys Medical 2019 © Roots Analysis
36
36
Other Recent Offerings
37
37
About Roots Analysis
We provide deep expertise, experience and knowledge in bio-pharmaceutical and
allied markets
Example Markets Example Capabilities

▪Diagnostics ▪Market landscaping
Capabilities
▪Emerging technologies ▪Competitive analysis
▪Medical devices ▪‘Value chain’ analysis
▪Therapeutic areas ▪Financial and business
▪Drug delivery planning
Markets
▪Clinical trials ▪Technology / product
benchmarking
▪Health & wellness
▪Drug pipeline evaluation
▪Pharmaceutical
packaging ▪Company profiling
38
38
The leading research house for professionals, analysts
and researchers for unbiased and insightful opinions
For more details, write to us
Sales / Subscriptions: sales@rootsanalysis.com
Other Queries: enquiry@rootsanalysis.com
For a truly global perspective

www.rootsanalysis.com
39
39

Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030

Uploaded by

Copyright:

You might also like

Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030

Uploaded by

Document Information

Copyright

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030

Uploaded by

Copyright:

Tracking the healthcare innovation

Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market

2019 © Roots Analysis

2019 © Roots Analysis

2019 © Roots Analysis

USD After the approval of multiple

High Capital Process Limited Existing concerns in this field have

Increasing expenditure by public

Market Demand Capacity Key

Recent Cost Price Emerging Company

Drivers and Market Forecast Primary

Industry Key Growth Future Trends /

Type of Application Therapeutic Scale of

Industry Stakeholders Client Feedback

Vectors and Gene Therapy Manufacturing Market

2019 © Roots Analysis

16 2009 ✓ ✓ ✓ ✓ ✓ ✓ ✓ 20mL to 200L

48 1995 ✓ ✓ ✓ 58% 41% 56%

35 1885 ✓ ✓ ✓ ✓ ✓ ✓ ✓ 20ml to 200L

Small-sized Industry Players Vaccines

Large Industry Players

Florida Germany Finland

19% Lentiviral 23% 16% xx

North America Europe Asia-Pacific

North America X Liters Europe X Liters Asia-Pacific X Liters

Vector Manufacturing Capacity Analysis:

Small-Sized Mid-Sized Large and Very

Viral and Non-Viral Vectors1 Viral and Non-Viral Vectors

Virus Based Bacteria Based Others (DNA / Transposon)

A management consulting firm for regenerative medicines

“ To overcome the challenges associated with the production of contaminant

Additional potential till 2030

Likely market size in 2025

XX Vector Type 6 Vector Type 3 XX

2025 2030 Market Share 2025 2030

Note 1: Illustrations are not as per actual scale

2019 © Roots Analysis

LICENSE TYPE (tick one)

Please invoice my company for _______________

PAYMENT AUTHORIZATION NOTE

2019 © Roots Analysis

20.9. Delphi Genetics

20.11. Novasep 2019 © Roots Analysis

2019 © Roots Analysis

2019 © Roots Analysis

Example Markets Example Capabilities

2019 © Roots Analysis

For a truly global perspective

2019 © Roots Analysis

You might also like